BloodThinnerHelp.com reports today on the latest development in Xarelto lawsuit filings. A new federally filed lawsuit was added to the Xarelto multidistrict litigation. The complaint was filed by the son of a man from Georgia who recently passed away due to an internal bleeding event that was allegedly caused by Xarelto usage. The full complaint can be downloaded here.
This most recent complaint was filed in the Xarelto MDL in Louisiana on March 20, 2015 under case number 2:15-cv-00886. The Xarelto MDL and Philadelphia Mass Tort Group have both been formed to expedite the trial process for all parties involved. The formation of these groups coordinates pretrial discovery and saves time in the litigation of these lawsuits since all of the plaintiffs involved are making similar allegations against defendants Bayer AG and Janssen Pharmaceuticals claiming that their blood thinner Xarelto caused serious injuries and death due to uncontrollable internal bleeding.
Lawsuit Claims Xarelto Side Effects Caused Wrongful Death
The son of the deceased, a Tennessee resident, alleges in the complaint that his father died from an uncontrollable internal bleeding event that is believed to be linked to his Xarelto usage. The complaint details that the deceased was initially prescribed Xarelto to treat atrial fibrillation, a heart condition, in November 2012. Xarelto was approved to treat this condition by the FDA. Unfortunately, in March 2013 the plaintiff’s father passed away due to complications from an internal bleeding event. The complaint states that this would not have happened if the plaintiff and his family knew about the risks that Xarelto presented before his father took the drug. If they knew these risks, they would have looked for a safer alternative.
The complaint alleges that Xarelto’s manufacturers knew that the blood thinner could potentially cause irreversible, serious internal bleeding events and concealed this knowledge from the public. The complaint also outlines how the defendants allegedly did not adequately warn the medical community and patients about Xarelto’s lack of an antidote and also did not advise the medical community on ways to stabilize a patient taking Xarelto in the event that an internal bleeding injury occurred.
Xarelto’s Dangerous Lack of Antidote
According to the National Heart, Lung, and Blood Institute, atrial fibrillation is a very common irregular heart beat that is suffered by more than 3 million people per year in the United States. A recognized treatment for atrial fibrillation in the medical community is with blood thinners. The danger with prescribing Xarelto as opposed to more traditional blood thinners such as Warfarin is that unlike traditional blood thinners, Xarelto does not have an antidote. There is no way to reverse the anticoagulant effects of the drug in an internal bleeding emergency.
“We encourage anybody who feels that they may have been injured by their Xarelto usage to contact us immediately.” Xarelto attorney Marc Goldich said, “We expect to see more Xarelto lawsuits come forward as the litigation proceeds.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.